Helen E Rollison, Pallabi Mitra, Hugues Chanteux, Zhizhou Fang, Xiaomin Liang, Seong Hee Park, Chester Costales, Imad Hanna, Nilay Thakkar, James M Vergis, Daniel A J Bow, Kathleen M Hillgren, Jochen Brumm, Xiaoyan Chu, Cornelis E C A Hop, Yurong Lai, Cindy Yanfei Li, Kelly M Mahar, Laurent Salphati, Rucha Sane, Hong Shen, Kunal Taskar, Mitchell E Taub, Kimio Tohyama, Christine Xu, Katherine S Fenner
The IQ Transporter Working Group had a rare opportunity to analyse a cross-pharma collation of in vitro data and assay methods for the evaluation of drug transporter substrate and inhibitor potential. Experiments were generally performed in accordance with regulatory guidelines. Discrepancies, such as not considering the impact of pre-incubation for inhibition and free or measured in vitro drug concentrations, may be due to the retrospective nature of the dataset and analysis. Lipophilicity was a frequent indicator of cross-transport inhibition (P-gp, BCRP, OATP1B and OCT1) with high molecular weight ({greater than or equal to}500 Da) also common for OATP1B and BCRP inhibitors...
May 2, 2024: Drug Metabolism and Disposition: the Biological Fate of Chemicals